Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 3/20 | 0.57 |
| ▸ | PKM | P14618 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.49 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.45 |
| ▸ | APOB | P04114 | 4/20 | 0.45 |
| ▸ | MTTP | P55157 | 4/20 | 0.45 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6809184 | 0.95 | SMO (0.56) | SMOPKMLMNAMAPTTRPV1 | |
| SCHEMBL6804166 | 0.92 | SMO (0.61) | SMOLMNATRPV1KCNMA1APOB | |
| SCHEMBL6803739 | 0.92 | SMO (0.48) | SMOPKMLMNAMAPTTRPV1 | |
| SCHEMBL6641308 | 0.91 | PKM (0.51) | SMOPKMLMNAMAPTTRPV1 | |
| SCHEMBL6791040 | 0.90 | PKM (0.49) | SMOPKMLMNAMAPT | |
| SCHEMBL6792904 | 0.88 | SMO (0.61) | SMOLMNAMAPTTRPV1APOB | |
| SCHEMBL6792248 | 0.87 | SMO (0.60) | SMOTRPV1APOBMTTP | |
| SCHEMBL6788777 | 0.87 | SMO (0.60) | SMOLMNAMAPTTRPV1APOB | |
| SCHEMBL6805454 | 0.87 | SMO (0.60) | SMOLMNAMAPTTRPV1APOB | |
| SCHEMBL6792167 | 0.87 | SMO (0.60) | SMOLMNAMAPTTRPV1APOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157866-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157866-A1 | Amide compounds | APOB, NR1H2, NR1H3 | SMO 4390/4885PKM 3470/4885LMNA 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.